LCN2 and chronic kidney disease: Although emerging biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL) offer promise for early detection of severe AKI, they remain underutilized and lack specificity in distinguishing AKI from CKD [5,7,9,10].